These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1315 related items for PubMed ID: 17229162

  • 1. Global update on defining and treating high-risk localized prostate cancer with leuprorelin: a USA perspective--identifying men at diagnosis who are at high risk of prostate cancer death after surgery or radiation therapy.
    D'Amico A.
    BJU Int; 2007 Jan; 99 Suppl 1():13-6; discussion 17-8. PubMed ID: 17229162
    [Abstract] [Full Text] [Related]

  • 2. Predictors of prostate cancer-specific mortality after radical prostatectomy or radiation therapy.
    Zhou P, Chen MH, McLeod D, Carroll PR, Moul JW, D'Amico AV.
    J Clin Oncol; 2005 Oct 01; 23(28):6992-8. PubMed ID: 16192586
    [Abstract] [Full Text] [Related]

  • 3. Predictors of mortality after androgen-deprivation therapy in patients with rapidly rising prostate-specific antigen levels after local therapy for prostate cancer.
    Rodrigues NA, Chen MH, Catalona WJ, Roehl KA, Richie JP, D'Amico AV.
    Cancer; 2006 Aug 01; 107(3):514-20. PubMed ID: 16795068
    [Abstract] [Full Text] [Related]

  • 4. Time to prostate-specific antigen nadir after androgen suppression therapy for postoperative or postradiation PSA failure and risk of prostate cancer-specific mortality.
    Chung CS, Chen MH, Cullen J, McLeod D, Carroll P, D'Amico AV.
    Urology; 2008 Jan 01; 71(1):136-40. PubMed ID: 18242382
    [Abstract] [Full Text] [Related]

  • 5. Time to an undetectable prostate-specific antigen (PSA) after androgen suppression therapy for postoperative or postradiation PSA recurrence and prostate cancer-specific mortality.
    D'Amico AV, McLeod DG, Carroll PR, Cullen J, Chen MH.
    Cancer; 2007 Apr 01; 109(7):1290-5. PubMed ID: 17315162
    [Abstract] [Full Text] [Related]

  • 6. Cancer-specific mortality after radiation therapy with short-course hormonal therapy or radical prostatectomy in men with localized, intermediate-risk to high-risk prostate cancer.
    Tsai HK, Chen MH, McLeod DG, Carroll PR, Richie JP, D'Amico AV.
    Cancer; 2006 Dec 01; 107(11):2597-603. PubMed ID: 17039498
    [Abstract] [Full Text] [Related]

  • 7. Prostate cancer-specific mortality after radical prostatectomy or external beam radiation therapy in men with 1 or more high-risk factors.
    D'Amico AV, Chen MH, Catalona WJ, Sun L, Roehl KA, Moul JW.
    Cancer; 2007 Jul 01; 110(1):56-61. PubMed ID: 17530618
    [Abstract] [Full Text] [Related]

  • 8. Six-month androgen suppression plus radiation therapy compared with radiation therapy alone for men with prostate cancer and a rapidly increasing pretreatment prostate-specific antigen level.
    D'Amico AV, Loffredo M, Renshaw AA, Loffredo B, Chen MH.
    J Clin Oncol; 2006 Sep 01; 24(25):4190-5. PubMed ID: 16943536
    [Abstract] [Full Text] [Related]

  • 9. Duration of testosterone suppression and the risk of death from prostate cancer in men treated using radiation and 6 months of hormone therapy.
    D'Amico AV, Renshaw AA, Loffredo B, Chen MH.
    Cancer; 2007 Oct 15; 110(8):1723-8. PubMed ID: 17828774
    [Abstract] [Full Text] [Related]

  • 10. Undetectable prostate specific antigen at 6-12 months: a new marker for early success in hormonally treated patients after prostate brachytherapy.
    Miller N, Smolkin ME, Bissonette E, Theodorescu D.
    Cancer; 2005 Jun 15; 103(12):2499-506. PubMed ID: 15852361
    [Abstract] [Full Text] [Related]

  • 11. Global update on defining and treating high-risk localized prostate cancer with leuprorelin: an Asian perspective.
    Mizokami A, Ueno S, Fukagai T, Ito K, Ehara H, Kinbara H, Origasa H, Usami M, Namiki M, Akaza H.
    BJU Int; 2007 Jan 15; 99 Suppl 1():6-9; discussion 17-8. PubMed ID: 17229160
    [Abstract] [Full Text] [Related]

  • 12. Phase I-II trial evaluating combined intensity-modulated radiotherapy and in situ gene therapy with or without hormonal therapy in treatment of prostate cancer-interim report on PSA response and biopsy data.
    Teh BS, Ayala G, Aguilar L, Mai WY, Timme TL, Vlachaki MT, Miles B, Kadmon D, Wheeler T, Caillouet J, Davis M, Carpenter LS, Lu HH, Chiu JK, Woo SY, Thompson T, Aguilar-Cordova E, Butler EB.
    Int J Radiat Oncol Biol Phys; 2004 Apr 01; 58(5):1520-9. PubMed ID: 15050332
    [Abstract] [Full Text] [Related]

  • 13. Influence of body mass index on prostate-specific antigen failure after androgen suppression and radiation therapy for localized prostate cancer.
    Efstathiou JA, Chen MH, Renshaw AA, Loffredo MJ, D'Amico AV.
    Cancer; 2007 Apr 15; 109(8):1493-8. PubMed ID: 17340594
    [Abstract] [Full Text] [Related]

  • 14. Prostate-cancer-specific survival and clinical progression-free survival in men with prostate cancer treated intermittently with testosterone-inactivating pharmaceuticals.
    Scholz M, Lam R, Strum S, Jennrich R, Johnson H, Trilling T.
    Urology; 2007 Sep 15; 70(3):506-10. PubMed ID: 17905106
    [Abstract] [Full Text] [Related]

  • 15. Prostate-specific antigen-based serial screening may decrease prostate cancer-specific mortality.
    Efstathiou JA, Chen MH, Catalona WJ, McLeod DG, Carroll PR, Moul JW, Roehl KA, D'Amico AV.
    Urology; 2006 Aug 15; 68(2):342-7. PubMed ID: 16904449
    [Abstract] [Full Text] [Related]

  • 16. Identifying men diagnosed with clinically localized prostate cancer who are at high risk for death from prostate cancer.
    D'Amico AV, Hui-Chen M, Renshaw AA, Sussman B, Roehl KA, Catalona WJ.
    J Urol; 2006 Dec 15; 176(6 Pt 2):S11-5. PubMed ID: 17084157
    [Abstract] [Full Text] [Related]

  • 17. Radical prostatectomy and adjuvant endocrine therapy for prostate cancer with or without preoperative androgen deprivation: Five-year results.
    Homma Y, Akaza H, Okada K, Yokoyama M, Moriyama N, Usami M, Hirao Y, Tsushima T, Sakamoto A, Ohashi Y, Aso Y, Prostate Cancer Study Group.
    Int J Urol; 2004 May 15; 11(5):295-303. PubMed ID: 15147545
    [Abstract] [Full Text] [Related]

  • 18. Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy.
    D'Amico AV, Chen MH, Roehl KA, Catalona WJ.
    N Engl J Med; 2004 Jul 08; 351(2):125-35. PubMed ID: 15247353
    [Abstract] [Full Text] [Related]

  • 19. Total androgen blockade versus a luteinizing hormone-releasing hormone agonist alone in men with high-risk prostate cancer treated with radiotherapy.
    Nanda A, Chen MH, Moran BJ, Braccioforte MH, Dosoretz D, Salenius S, Katin M, Ross R, D'Amico AV.
    Int J Radiat Oncol Biol Phys; 2010 Apr 08; 76(5):1439-44. PubMed ID: 19540066
    [Abstract] [Full Text] [Related]

  • 20. Cancer-specific mortality after surgery or radiation for patients with clinically localized prostate cancer managed during the prostate-specific antigen era.
    D'Amico AV, Moul J, Carroll PR, Sun L, Lubeck D, Chen MH.
    J Clin Oncol; 2003 Jun 01; 21(11):2163-72. PubMed ID: 12775742
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 66.